Gerber's concerns mirrored those expressed by economist Peter Schiff, who accused Strategy of running an unsustainable ...

If the company is forced to offload even 100,000 of its 649,870 coins to meet obligations, it could trigger a systemic ...

Many users feel they’re talking to a real person. Scientists say it’s time to consider whether they’re onto something.

A deep learning framework enhances medical image recognition by optimizing RNN architectures with LSTM, GRU, multimodal fusion, and CNN integration. It improves dynamic lesion detection, temporal ...

The European Space Agency’s recently published Zero Debris Technical Booklet, developed through a collaborative community ...

Understand flash loan security risks and exploits. Learn how attackers manipulate oracles and governance, and discover best ...

The HackerEarth platform itself is pretty standard for online coding tests. You’ll have a code editor where you write your ...

Your LeetCode profile is more than just a list of solved problems. It’s a story about your coding journey, your ...

Ongoing Phase 1b/2 Trial of the Allosteric MEK1/2 Inhibitor REC-4881 as Monotherapy (FAP): Updated Safety and Efficacy Najat Khan, Ph.D ., Chief R&D and Chief Commercial Officer and incoming CEO and ...

Recursion (Nasdaq: RXRX) a leading clinical stage TechBio company decoding biology to radically improve lives, announced today that it will present ...

Najat Khan, PhD, unpacks realistic timelines for AI-based drugs to make clinical impact and her priorities for Recursion as incoming CEO.

The latest announcement is out from Recursion Pharmaceuticals ( ($RXRX) ). On November 26, 2025, Recursion Pharmaceuticals filed a prospectus ...